{"id":"W4399394861","doi":"10.1200/jco.2024.42.16_suppl.5063","title":"Matching-adjusted indirect comparisons (MAICs) of talazoparib plus enzalutamide (TALA+ENZA) versus olaparib plus abiraterone and prednisone/prednisolone (OLAP+AAP) for first-line (1L) therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair mutations (HRRm)/BRCAm.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Enzalutamide; Eribulin; Abiraterone; Olaparib; Prostate cancer; Prednisone; CYP17A1; Internal medicine; Bicalutamide; Oncology; Prednisolone; Urology; Androgen receptor; Cancer; Metastatic breast cancer; Poly ADP ribose polymerase; Breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008052567,0.001067706,0.001745057,0.0007218994,0.0002038567,0.0006050235,0.001003967,0.0006525854,0.004671298],"category_scores_gemma":[0.01634312,0.0002734927,0.004382751,0.0005607295,0.0004879043,0.0007290766,0.001032172,0.001496224,0.0002504932],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007420116,"about_ca_system_score_gemma":0.0007214054,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001152751,"about_ca_topic_score_gemma":0.002268407,"domain_scores_codex":[0.9908512,0.006925529,0.0004939602,0.000918454,0.0004611459,0.0003497053],"domain_scores_gemma":[0.9928603,0.004667246,0.001347032,0.0005785249,0.0002099257,0.0003369558],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"simulation_or_modeling","study_design_scores_codex":[0.8075869,0.001366169,0.05419719,0.002938953,0.07624671,0.0001314049,0.0001901772,0.00517904,0.00216223,0.001626709,0.002719547,0.04565489],"study_design_scores_gemma":[0.2098753,0.3178924,0.2586572,0.00067725,0.136988,0.0005147365,0.0005375803,0.04423163,0.008050294,0.007731525,0.01462797,0.0002160147],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9803382,0.005411205,0.004889703,0.000231445,0.0004649058,0.001799389,0.003930574,0.00008689705,0.002847613],"genre_scores_gemma":[0.9930981,0.0003775978,0.002992342,0.0001854463,0.00009034328,0.00126391,0.001267905,0.00001535263,0.0007090484],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008052567,"threshold_uncertainty_score":0.04258657,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1287155339789746,"score_gpt":0.4297501000838353,"score_spread":0.3010345661048607,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}